Metabolic & Cardiometabolic
adolescent anabolic-steroid use decreases adult height via growth-plate closure
In plain terms: Can teenage anabolic-steroid use permanently stunt height?
Yes — androgens aromatize to estrogen, which prematurely fuses the growth plates; this is well-established endocrinology (high-dose testosterone is even used clinically to close plates in very tall teens), so steroid use before growth finishes can permanently limit height.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Population patterns (Observational)
How the studies fall
What the evidence shows
The endocrinology is well established: androgens aromatise to oestrogen, which advances skeletal maturation and prematurely fuses the growth plates, and excessive prepubertal androgen exposure causes early epiphyseal closure and short stature. Direct evidence in adolescents using steroids recreationally is thin, resting on mechanism and on clinical androgen treatment in other conditions.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Witbreuk M, van Kemenade FJ, van der Sluijs JA, Jansma EP, Rotteveel J, van Royen BJ 2013 · Journal of children's orthopaedics | mechanism | supports | low | Systematic review on slipped capital femoral epiphysis describes how activation of the gonadal axis and the resulting GH-IGF-1 axis surge drive pubertal growth-plate (physis) weakening and eventual cessation at the end of puberty. |
| Wit JM 2021 · Frontiers in endocrinology | mechanism | supports | low | Second, the combination of a GnRHa with an anabolic steroid was investigated in two studies with an apparently positive effect on AH compared with matched controls ( 34 , 35 ) (LoE 3), but since then no more data have been presented. |
| Thodberg HH, Aksglaede L, Juul A, Davis SM, Ross J 2026 · Scientific reports | observational | supports | low | Case-control trial of oxandrolone vs placebo in 90 boys with Klinefelter syndrome showed androgen treatment accelerated bone age advancement (0.24, 0.77, 1.24, 1.43 years at 6/12/18/24 months), detectable by 6 months. Bone age advancement i |
| Vanderschueren D, Vandenput L, Boonen S 2005 · Horm Res | mechanism | supports | moderate | Androgens and their aromatized estrogens drive skeletal maturation and epiphyseal fusion during puberty. |
| Matsuo K, Fujieda K 2006 · Nihon Rinsho | mechanism | supports | moderate | Excessive prepubertal androgens advance bone maturation and cause premature epiphyseal closure and short stature. |
| Juul A 2001 · Growth Horm IGF Res | mechanism | supports | moderate | High sex-steroid exposure, via aromatization to estrogen, drives epiphyseal fusion and terminates linear growth. |
| Savage MO, Scommegna S, Carroll PV, Ho JT, Monson JP, Besser GM, Grossman AB 2002 · Horm Res | observational | supports | moderate | Chronic androgen excess causes early epiphyseal fusion and adult short stature in affected children. |
| Mohamed S, Alkofide H, Adi YA, Amer YS, AlFaleh K 2019 · The Cochrane database of systematic reviews | meta-analysis | mixed | high | [SCOPE: therapeutic low-dose oxandrolone in Turner-syndrome girls, NOT illicit supraphysiologic AAS abuse in adolescent boys] Cochrane meta-analysis of 6 RCTs (498 adolescent girls with Turner syndrome) found oxandrolone added to growth hor |
| Jaruratanasirikul S, Thaiwong M 2011 · J Med Assoc Thai | observational | supports | moderate | Untreated early sex-steroid-driven puberty results in short adult stature from premature growth-plate closure. |
| Smith EP, Korach KS 1996 · Baillieres Clin Endocrinol Metab | mechanism | supports | moderate | Estrogen, largely from aromatized androgen, is the principal driver initiating and completing epiphyseal closure. |
| Hoffman JR, Kraemer WJ, Bhasin S, Storer T, Ratamess NA, Haff GG, Willoughby DS, Rogol AD 2009 · J Strength Cond Res | observational | supports | low | An NSCA position stand notes androgen use in adolescents risks premature epiphyseal closure and compromised growth. |
| Meazza C, Gertosio C, Giacchero R, Pagani S, Bozzola M 2017 · Ital J Pediatr | mechanism | supports | low | High-dose testosterone is used clinically in tall adolescents to induce epiphyseal fusion and reduce final height. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.